
Valneva SE (VALN) Stock Forecast & Price Target
Valneva SE (VALN) Analyst Ratings
Bulls say
Valneva SE is positioned favorably due to an increased commercial uptake assumption for its vaccine candidate VLA15 in Europe, aligning it closer to expectations in the United States. The company's recent report of strong immune responses following a third booster dose of VLA15 in both adults and children further bolsters confidence in its pipeline. Despite the unexpected suspension of the Ixchiq vaccine by the FDA, the overall revenue generation from commercialized vaccines and ongoing vaccine development programs supports a positive outlook for future cash flows.
Bears say
Valneva faces significant challenges that contribute to a negative outlook, primarily due to clinical and regulatory risks that could hinder its vaccine development efforts. Recent safety concerns surrounding its Ixchiq vaccine, despite claims of superior long-term protection, could reduce its competitiveness compared to rivals such as Bavarian Nordic’s chikungunya vaccine. Additionally, the removal of US Ixchiq sales from projections, coupled with anticipated limited commercial uptake in Europe, signals a potential decline in revenue generation which could adversely impact the company’s financial standing.
This aggregate rating is based on analysts' research of Valneva SE and is not a guaranteed prediction by Public.com or investment advice.
Valneva SE (VALN) Analyst Forecast & Price Prediction
Start investing in Valneva SE (VALN)
Order type
Buy in
Order amount
Est. shares
0 shares